title: A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods.
abstract: Cyclooxygenase (COX, EC 1.14.99.1) inhibitor-nitric oxide (NO) donor (CINOD) hybrid compounds represent an attractive alternative to NSAID and coxib therapy. This report compares two CINODs, NMI-1182 (naproxen-glyceryl dinitrate) and AZD3582 (naproxen-n-butyl nitrate), for their ability to inhibit COX-1 and -2, deliver bioavailable nitric oxide, and release naproxen, using in vitro biochemical and pharmacological methods. In human whole blood, both CINODs showed inhibition, comparable to naproxen, of both COX isozymes and slowly released naproxen. Both CINODs donated bioavailable NO, as detected by cGMP induction in the pig kidney transformed cell line, LLC-PK1, but NMI-1182 was more potent by 30-100 times than AZD3582, GTN, GDN, and ISDN and considerably faster in inducing cGMP synthesis than AZD3582. The nitrate groups of GTN, NMI-1182, and AZD3582 appeared to be bioactivated via a common pathway, since each compound desensitized LLC-PK1 cells to subsequent challenge with the other compounds. Similar cGMP induction also occurred in normal, untransformed cells (human renal proximal tubule epithelial cells and hepatocytes from man, rat, and monkey); again, NMI-1182 was superior to AZD3582. NMI-1182 was also the more metabolically labile compound, releasing more absolute nitrate and nitrite (total NO(x)) in human stomach (in which NO is salutary) and liver S9 homogenates. Naproxen was also more rapidly freed from NMI-1182 than AZD3582 in human stomach, although liver S9 hydrolyzed both CINODs with similar rates. These in vitro tests revealed that NMI-1182 may be a better CINOD than AZD3582 because of its superior NO donating and naproxen liberating properties.
authors.affiliation: Departments of Biology, 125 Spring St., Lexington, MA 02421, USA. dyoung@nitromed.com
authors.forename: Delano V
authors.initials: DV
authors.lastname: Young
authors.forename: Edward D
authors.initials: ED
authors.lastname: Cochran
authors.forename: Vijay
authors.initials: V
authors.lastname: Dhawan
authors.forename: Richard A
authors.initials: RA
authors.lastname: Earl
authors.forename: James L
authors.initials: JL
authors.lastname: Ellis
authors.forename: David S
authors.initials: DS
authors.lastname: Garvey
authors.forename: David R
authors.initials: DR
authors.lastname: Janero
authors.forename: Subhash P
authors.initials: SP
authors.lastname: Khanapure
authors.forename: L Gordon
authors.initials: LG
authors.lastname: Letts
authors.forename: Terry L
authors.initials: TL
authors.lastname: Melim
authors.forename: Madhavi G
authors.initials: MG
authors.lastname: Murty
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Shumway
authors.forename: Shiow-Jyi
authors.initials: SJ
authors.lastname: Wey
authors.forename: Irina S
authors.initials: IS
authors.lastname: Zemtseva
authors.forename: William M
authors.initials: WM
authors.lastname: Selig
mesh_terms: D006152:Cyclic GMP / Q000096:biosynthesis; D051545:Cyclooxygenase 1 / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D006801:Humans; D008099:Liver / Q000378:metabolism; D009281:Naphthalenes / Q000493:pharmacokinetics / Q000494:pharmacology*; D009288:Naproxen / Q000494:pharmacology / Q000031:analogs & derivatives; D009569:Nitric Oxide / Q000096:biosynthesis; D020030:Nitric Oxide Donors / Q000494:pharmacology*
chemical_list: D016861:Cyclooxygenase Inhibitors; C505683:NMI-1182; D009281:Naphthalenes; D020030:Nitric Oxide Donors; C111751:naproxen-n-butyl nitrate; D009569:Nitric Oxide; D009288:Naproxen; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D006152:Cyclic GMP